New diagnostic strategies in the detection and staging of bladder cancer

Current Opinion in Urology

Volumn 13, Issue 5, 2003, Pages 351-355

  Jichlinski, Patrice ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bladder neoplasm; Cystoscopy; Cytology; Fluorescence cystoscopy; Urine marker

Indexed keywords

MATRIX PROTEIN; MICROSATELLITE DNA; MINICHROMOSOME MAINTENANCE PROTEIN; TELOMERASE; TUMOR ANTIGEN;

BLADDER CARCINOMA; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CARCINOMA IN SITU; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DNA METHYLATION; ENDOSCOPY; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE POLICY; HEALTH SURVEY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; MINICHROMOSOME; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SUPERFICIAL CANCER; URINALYSIS; VIRTUAL REALITY;

DIAGNOSTIC TECHNIQUES, UROLOGICAL; HUMANS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 0043263876     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200309000-00001     Document Type: Review

References (33)

1. Saad A, Hanbury DC, McNicholas TA, et al. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002; 89:369-373. The first study describing the combination of different urine marker tests. Is it really wise?
2. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167:1573-1583. An excellent and complete review on the management of T1 bladder cancer.
3. Pfister C, Chautard D, Devonec M, et al. ImmunoCyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003; 169:921-924. This large prospective study (694 patients in 10 centres) provides reliable information on ImmunoCyt sensitivity and specificity in daily clinical practice.
4. D'Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol 2002; 42:417-425. An express review on fluorescence cystoscopy.
5. Jichlinski R, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer - a multicenter study. J Urol 2003; 170:226-229. First multicentric study on Hexvix fluorescence cystoscopy which emphasizes the use of the method to detect CIS.
6. Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002; 168:475-478. A multicentric random study on 129 patients, looking at the significant reduction rate of residual tumours as the result of TUR with fluorescence cystoscopy compared with white light.
7. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol August 2003; 170. This paper describes PpIX fluorescence accumulation in human bladder cancer tumour specimen under different conditions of ALA and HAL instillations.
8. Marberger M, Witjes F, Schmeller N, et al. Hexyl aminolevulinate (HAL) fluorescence versus standard cystoscopy for detecting carcinoma in situ (CIS) of the bladder [Abstract]. J Urol 2003; 169 (Suppl.):1006.
9. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol 2003; 18:259-274. An excellent review, which goes broadly beyond the scope of this paper.
10. Zaak D, Stepp H, Baumgartner R, et al. Ultraviolet-excited (308 nm) autofluorescence for bladder cancer detection. Urology 2002; 60:1029-1033. This work of the group of Munich explores a specific way to reduce the false-positive rate of fluorescence cystoscopy.
11. Zheng W, Lau W, Cheng C, et al. Optimal excitation-emission wavelengths for autofluorescence diagnosis of bladder tumors. Int J Cancer 2003; 104:477-481.
12. Lammle M, Beer A, Settles M, et al. Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. Am J Roentgenol 2002; 178:1483-1488. Magnetic resonance virtual cystoscopy was found to have a detection rate of 70% of tumours less than 1 cm and 100% of tumours greater than 1 cm.
13. Mhawech P, Iselin C, Pelte MF. Value of immunohistochemistry in staging T1 urothelial bladder carcinoma. Eur Urol 2002; 42:459-463. This retrospective study shows that a specific staining of tumour and muscle fibres can reduce the interobserver variation between pathologists and helps in better disease staging. A prospective analysis is warranted.
14. Shvarts O, Han KR, Seltzer M, et al. Positron emission tomography in urologic oncology [Review]. Cancer Control 2002; 9:335-342. This review sets the place of positron emission tomography in oncological urology.
15. Raitanen MP, Aine R, Rintala E, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002; 41:284-289.
16. Placer J, Espinet B, Salido M, et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002; 42:547-552. A monocentric study that shows the importance of a well-codified technique for an accurate FISH test interpretation in clinical practice.
17. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168:1950-1954. A multicentric study with much information showing that the FISH test is clearly more sensitive than BTA and cytology in bacillus Calmette-Guérin-treated patients.
18. Lodde M, Mian C, Negri G, et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 2003; 61:243-247. This paper confirms the value of the ImmunoCyt test, with an interesting comment on the consequences of its introduction in clinical practice.
19. Mezzelani A, Dagrada G, Alasio L, et al. Detection of bladder cancer by multitarget multicolour FISH: comparative analysis on archival cytology and paraffin-embedded tissue. Cytopathology 2002; 13:317-325. A complete correspondence of the FISH alteration pattern was found between cytological and histological samples in each case investigated. The secondary application of FISH on archival cytological material interpreted as inadequate may avoid false-negative results.
20. Sawczuk IS, Pickens CL, Vasa UR, et al. DD23 Biomarker. A prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 2002; 7:185-190. Although useful in skilled hands, this immunostaining test seems to be exposed to a more subjective interpretation than FISH and ImmunoCyt.
21. Parrella P, Seripa D, Matera MG, et al. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett 2003; 190:73-77.
22. Isurugi K, Suzuki Y, Tanji S, Fujioka T. Detection of the presence of catalytic subunit mRNA associated with telomerase gene in exfoliated urothelial cells from patients with bladder cancer. J Urol 2002; 168:1574-1577.
23. Neves M, Ciofu C, Larousserie F, et al. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 2002; 167:1276-1281. In this study the LOH test was found to have 100% specificity and 96% sensitivity. It seems less dependent on urine sediment quality than hTERT mRNA detection and cytology.
24. Berger AP, Parson W, Stenzl A, et al. Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. Eur Urol 2002; 41:532-539. Microsatellite alterations are very common in human bladder cancer. The problem is the choice of a microsatellite marker set representative of the tumour genetic instability. In this study, the alterations were found in 87% of cases, but none in grade 1 tumours.
25. Boman H, Hedelin H, Jacobsson S, Holmang S. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol 2002; 168:1955-1959. How to interpret haematuria? Urine marker (NMP22, BTA stat, UBC) sensitivity values are identical irrespective of whether macrohaematuria is the initial symptom. As for all tested markers, the sensitivity of dipstick haematuria is higher for high-grade than low-grade tumours.
26. Mahnert B, Tauber S, Kriegmair M, et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay) - useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 2003; 41:104-110. Excellent information on all urological conditions susceptible to modify the results of current urine markers.
27. Wald M, Halachmi S, Amiel G, et al. Bladder tumor antigen stat test in non-urothelial malignant urologic conditions. Isr Med Assoc J 2002; 4:174-175.
28. Fradet Y. Recent advances in the management of superficial bladder tumors [Review]. Can J Urol 2002; 9:1544-1550. A good review on the subject with a meta-analysis comparing current standard cytology, urine markers and ImmunoCyt.
29. Friedrich MG, Hellstern A, Toma MI, et al. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol 2003; 43:146-151.
30. Stoeber K, Swinn R, Prevost AT, et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 2002; 94:1071-1079. Mcm proteins play a critical regulatory role in the initiation of DNA replication and identify both proliferating cells and non-proliferating cells with proliferative potential. In that way, Mcm protein expression is a more sensitive marker than is the expression of conventional proliferative markers.
31. Goessl C, Muller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies [Review]. Eur Urol 2002; 41:668-676. This excellent review focuses on the fantastic potential of the DNA-based detection of urological malignancies in body fluids.
32. Amira N, Mourah S, Rozet F, et al. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 2002; 101:293-297. An interesting discussion about the necessary steps for the introduction of microsatellite analysis in clinical practice.
33. Valenzuela MT, Galisteo R, Zuluaga A, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 2002; 42:622-630.